An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
about
Biological markers of amyloid beta-related mechanisms in Alzheimer's diseaseBiomarkers of Alzheimer's diseaseFluid Biomarkers in Clinical Trials of Alzheimer's Disease TherapeuticsA window into the heterogeneity of human cerebrospinal fluid Aβ peptidesDetection and Identification of Bioanalytes with High Resolution LSPR Spectroscopy and MALDI Mass Spectrometry.High-throughput and targeted in-depth mass spectrometry-based approaches for biofluid profiling and biomarker discovery.Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease.Iowa variant of familial Alzheimer's disease: accumulation of posttranslationally modified AbetaD23N in parenchymal and cerebrovascular amyloid depositsRecent cerebrospinal fluid biomarker studies of Alzheimer's disease.Tissue transglutaminase-mediated glutamine deamidation of beta-amyloid peptide increases peptide solubility, whereas enzymatic cross-linking and peptide fragmentation may serve as molecular triggers for rapid peptide aggregationNeuroprotective and cognitive enhancing activity of the fermented Bozhougyiqi-Tang.A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer diseaseMatrix metalloproteinase 2 (MMP-2) degrades soluble vasculotropic amyloid-beta E22Q and L34V mutants, delaying their toxicity for human brain microvascular endothelial cellsThe amyloid-β isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's diseaseLigustrazine phosphate ethosomes for treatment of Alzheimer's disease, in vitro and in animal model studies.Biological markers for early detection and pharmacological treatment of Alzheimer's disease.Intracerebral Injection of Metal-Binding Domain of Aβ Comprising the Isomerized Asp7 Increases the Amyloid Burden in Transgenic Mice.Effects of BACE1 haploinsufficiency on APP processing and Aβ concentrations in male and female 5XFAD Alzheimer mice at different disease stagesFluid biomarkers in Alzheimer disease.Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's diseaseTargeting the glycoproteomeSmall molecule inhibitors of Abeta assembly.Current state and future directions of neurochemical biomarkers for Alzheimer's disease.Clinical proteomics in neurodegenerative disorders.Kinetic and structural characterization of amyloid-β peptide hydrolysis by human angiotensin-1-converting enzyme.Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker?Targeted proteomics in Alzheimer's disease: focus on amyloid-beta.The AbetaCs of Abeta-cleaving proteases.Update on amyloid-beta homeostasis markers for sporadic Alzheimer's disease.Aspects of beta-amyloid as a biomarker for Alzheimer's disease.Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies.The use of mass spectrometry to study amyloid-β peptides.Cerebrospinal fluid biomarkers for Alzheimer's disease: the present and the future.Analytical aspects of molecular Alzheimer's disease biomarkers.Alkaloids as a source of potential anticholinesterase inhibitors for the treatment of Alzheimer's disease.Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.Prions and prion-like pathogens in neurodegenerative disorders.Amyloid-β as a biomarker for Alzheimer's disease: quantification methods in body fluids.Biomarkers in Sporadic and Familial Alzheimer's Disease.Selecting Aβ isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel.
P2860
Q24622136-4D0D89D4-95EA-435B-8ED6-E895C75521E6Q24650667-0CCDA16D-E78E-4892-84B0-C2C0353A5D19Q26784569-50423286-AEC4-4FEB-9CBE-FCC8FF8EC0AAQ27010785-4D2A1498-9132-4CF5-BA81-D540F7E29E51Q33531695-D3BB8A4D-AF35-49ED-9C44-8951290E49D6Q33579375-EDC86D0D-9B54-4531-AE51-16814DF71C55Q33638748-DC5CDBA1-A474-48D2-948E-E3565A344F2CQ33745216-8F67DA02-A5FD-4DB8-807D-683F3768B090Q33766323-4F3D0E8A-DBCB-486A-8FA2-CDE24FF8157BQ33814180-5B0E5169-F302-4166-83D4-14C9B73DFA4FQ33833055-EA62688F-196E-4C87-8F76-9A5891DFA1E7Q33877903-6428E8C1-54D7-4A3A-9F49-A91FE7E4DDA4Q34094501-B16156B1-B5FD-4615-91AF-35CB310A48D5Q34151493-F9223E27-F403-4ABF-813F-91513FE8E8A4Q34194852-F1011CA5-C6C7-4F4E-87EB-D24515DB5E7CQ35237100-36A3E88D-74D8-4279-89BD-AF1A452B1B70Q35913908-B5DE4154-D4BA-4BC6-A5DC-1CC11FCD5DA2Q36113733-ED537E70-F54B-49DD-A1A8-9BFFB091C861Q36186513-9DA1C06C-0E42-4ED0-900B-7560172D13A7Q36337525-2CEEAE76-2ECA-481F-BA3B-662B3FF26DADQ36554714-41CB8E75-8B17-43CF-B54F-151066237474Q36911406-6E83E024-F9CE-4CC3-B772-7B5C4DE16EEBQ36985933-2501DA74-F14B-4570-9731-8F6E8EF285C2Q37086170-7EC3522F-3844-4A48-9536-C6410D683567Q37107046-2F35F049-27F9-4A80-9526-F513F3F2EDDAQ37118083-E5B099E2-2AAC-4364-8E18-DAE1A0EF0302Q37157835-9F4792FF-3E58-46AA-B5AE-31FDDB86E356Q37250796-02CF0E4F-31A2-4DBC-A5DF-D9FA0A5BFCE7Q37387103-593B7E1A-525B-46E1-BCE6-ABFC51B7092AQ37755129-B118F00F-D48D-4AFD-A60D-7B61F36A0DB1Q37800101-DB94237E-DFA9-4215-864F-AF2A5234887CQ37866222-EE2E5EE3-C748-4DBF-9CF9-AA69EFDC54E0Q37895052-B7D46DF0-EF46-4D5F-B912-73C1128771D6Q38037149-02F42E4D-F21A-4DF8-BE4D-83A97116BCB1Q38162961-F297D545-1DF3-4B77-A93F-927B1C9B22F9Q38210117-111DECFB-D775-472B-85C4-E35E04D9A4EEQ38273271-5203A6E0-A842-410B-8AE4-A6A07E8A8E5AQ38543843-366B3B0E-661E-4107-B469-767DC8EE698FQ38592041-BD4AAF9E-E764-49F6-AC52-DED43B2E054CQ39098473-F5603E13-A8FB-41AC-B156-133B19FEFE22
P2860
An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
@ast
An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
@en
type
label
An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
@ast
An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
@en
prefLabel
An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
@ast
An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
@en
P2093
P50
P1433
P1476
An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
@en
P2093
Anders Wallin
Niels Andreasen
Ulf Andreasson
P304
P356
10.1016/J.NEULET.2006.09.044
P407
P577
2006-10-17T00:00:00Z